M&A Deal Summary |
|
|---|---|
| Date | 2017-11-10 |
| Target | Obagi |
| Sector | Consumer Products |
| Buyer(s) | Haitong International Zhonghua Finance Acquisition Fund I |
| Sellers(s) | Bausch Health |
| Deal Type | Divestiture |
| Deal Value | 190M USD |
SEARCH BY
Haitong International is a private equity firm that invests in a variety of industries and situations. Haitong International is headquartered in Hong Kong, China.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Consumer Products M&A | 1 of 1 |
| Type: Divestiture M&A Deals | 1 of 1 |
| State: California M&A | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2017 M&A | 1 of 1 |
| Size (of disclosed) | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2021-11-15 |
Obagi
Long Beach, California, United States Obagi is a physician-dispensed brand in the dermo-cosmetic space, the highest-growth category in skin care. Obagi's product portfolio includes brands Obagi Nu-Derm®, Condition & Enhance®, Obagi-C® Rx, ELASTIDerm® and CLENZIDerm®. |
Sell | - |
| Category | Company |
|---|---|
| Sector | Life Science |
| Employees | 20,270 |
| Revenue | 9.6B USD (2024) |
Bausch Health is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, neurology, and branded generics. Bausch Health is based in Laval, Quebec.
| DEAL STATS | # |
|---|---|
| Overall | 9 of 10 |
| Sector: Consumer Products M&A | 5 of 5 |
| Type: Divestiture M&A Deals | 9 of 10 |
| State: California M&A | 2 of 2 |
| Country: United States M&A | 7 of 7 |
| Year: 2017 M&A | 6 of 6 |
| Size (of disclosed) | 4 of 5 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2017-06-08 |
iNova Pharmaceuticals
Singapore, Singapore iNova Pharmaceuticals is a developer and marketer of over-the-counter and prescription medicines. iNova Pharmaceuticals was founded in 1958 and is based in Singapore. |
Sell | $930M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2019-02-26 |
Synergy Pharmaceuticals - Certain Assets
New York, New York, United States Synergy Pharmaceuticals, Inc. - Certain Assets includes TRULANCE (plecanatide), a once-daily tablet approved for adults with chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C), and its investigational compound, dolcanatide, is an incremental peptide with established proof-of-concept studies in multiple GI conditions. |
Buy | $195M |
